Logo Image

Ken Cohen, MD, FACP

Articles by Ken Cohen, MD, FACP

Health Care System Integration

ByDavida Kruger, MSN, APN-BC, BC-ADM ,Jaime Murillo, MD, FACC, FASE ,Ian Neeland, MD, FAHA, FACC,Ken Cohen, MD, FACP,Jeremy Wigginton, MD, MBA, FAAFP

Experts discuss the role of continuous glucose monitoring (CGM)-derived metrics, particularly glucose management indicator (GMI), in the new Healthcare Effectiveness Data and Information Set (HEDIS) diabetes care measures and ACO quality targets, and how CGM-specific metrics are being incorporated into the National Committee for Quality Assurance (NCQA)’s quality measures and the implications for health plans.

CGM's Impact on Clinical Inertia

ByDavida Kruger, MSN, APN-BC, BC-ADM ,Jaime Murillo, MD, FACC, FASE ,Ian Neeland, MD, FAHA, FACC,Ken Cohen, MD, FACP,Jeremy Wigginton, MD, MBA, FAAFP

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

Key Benefits of CGM Technology

ByDavida Kruger, MSN, APN-BC, BC-ADM ,Jaime Murillo, MD, FACC, FASE ,Ian Neeland, MD, FAHA, FACC,Ken Cohen, MD, FACP,Jeremy Wigginton, MD, MBA, FAAFP

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with traditional monitoring based on recent clinical trial data, including research on cardiovascular risk reduction in noninsulin-treated T2D.